BioLink Life Sciences, a pharmaceutical firm focused on improvement of registered drugs, has received a Small Business Innovation Research (SBIR) grant for use in development of anemia treatment.
The amount of the Phase 1 award was not disclosed.
The grant, which was awarded by the U.S. Department of Agriculture, will be used in development of an iron supplement.
“Not everyone is aware that one of every four people suffers from iron deficiency, and this causes serious health effects and enormous economic losses,” said Deanna Nelson, BioLink’s president. “Iron has been used to fortify foods for many years, but all currently available iron supplements have significant limitations, particularly in individuals vulnerable to iron deficiency, infants, children, young women, the elderly, and those with chronic diseases.
“This SBIR grant validates our unique approach to improving iron delivery and the quality of life of vulnerable individuals around the world,” she added.
BioLink is working with researchers at Cornell University on the project.
The grant is the second BioLink has received for the anemia-related research.